Use: Preservative and antioxidant;Adhesive and sealants;Dyes/pigment
Submission Information:
Submitter name:DuPont
Submission date:10/15/1992
Was the submission provided under the Compliance Audit Program (CAP)?
Yes
What type of information was reported?
Chemical testing
What type of effects testing was established?
Human health effects
What is the submission type? ::
Initial submission
Is the submission related to other TSCA § 8(e) documents?
No
What Human Toxicity testing was submitted?
ACUTE TOXICITY:
Study Type
Acute oral toxicity (AOT)
Protocol/guideline
Other:Not reported
Year Study Performed1973
Was the Study
Measured
Duration of Study14 days
Species
Rat
StrainChR-CD
Sex of Organisms
Male
Number of Organisms per Group10
Test Substance PurityNot reported
VehicleWater
Dose/Concentration500, 550, 575, and 600 mg/kg
Route
Oral
Exposure periodSingle exposure (gavage)
Results based on critical effectThe following mortalities were observed: 0/10 (500), 1/10 (550), 4/10 (575), and 7/10 (600). Clinical signs included irregular respiration, lacrimation, prostration, pallor, belly-to-cage posture. Weight loss was observed at 600 mg/kg and transient weight loss for 2-14 days was observed at 500, 550, and 575 mg/kg. Histological changes for animals dosed at 550, 575, and 600 mg/kg that died included necrosis of the stomach and duodenal mucosa, pancreas, liver, lymphocytes of the thymus, lymph nodes, and spleen. Additionally, edema of the submucosal stomach and lung were noted, as well as, kidney abnormalities, testicular hemorrhage, and cardiac and gastric muscle atrophy were observed. In surviving rats, stomach lesions (polymorphonuclear leukocytes, hyperplasia of squamous epithelium, increase in fibrous connective tissue, focal atrophy of the stomach muscle) were observed. No histopathological changes were observed in the 500 mg/kg group. Based on the results, the submission sponsor finds that the oral LD50 is 585 mg/kg in male rats.